Cardiology Clinical Trials Doctors Medicine 
Velocity Clinical Research
MARCH 7, 2024
It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA , Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council , discusses their importance to patients yesterday, today, and tomorrow. You can also do that by researching, publishing and teaching.
Velocity Clinical Research
DECEMBER 6, 2023
In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. As a result, Sponsors and CROs can benefit from simplified access to international clinical research capabilities. and Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Velocity Clinical Research
JANUARY 3, 2024
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.
The Pharma Data
NOVEMBER 4, 2020
ULTOMIRIS is a prescription medicine used to treat: adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. Your doctor will decide if you need additional vaccination. INDICATIONS.
The Pharma Data
JULY 8, 2021
“We look forward to presenting the EMPEROR-Preserved results at ESC 2021, which should offer a significant breakthrough in cardiovascular medicine and a new hope for people with HFpEF, which is an increasingly prevalent public health issue. ” The EMPEROR-Preserved trial investigated Jardiance 10 mg compared with placebo. .”
The Pharma Data
NOVEMBER 4, 2020
Progressed European regulatory review and commercial preparations : Continued to support regulatory review of VASCEPA by the European Medicines Agency (EMA) with the expectation of an early 2021 approval of VASCEPA for commercial sale in Europe. The design of the REDUCE-IT study was published in March 2017 in Clinical Cardiology.
The Pharma Data
NOVEMBER 16, 2020
The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. 13 in the New England Journal of Medicine. If it’s more convenient together, why not?”
Expert insights. Personalized for you.
52 
Let's personalize your content